These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 26929609)

  • 21. [InoPro trial: collaboration between urologists and primary care physicians in the treatment of osteoporosis in prostate cancer patients].
    Laufer M; Keller T; Gershman V; Ferman Z; Sarid M; Leibovitch I
    Harefuah; 2014; 153(3-4):151-4, 240. PubMed ID: 24791553
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of expressions of treatment efficacy and out-of-pocket expenses on patient and physician interest in osteoporosis treatment: implications for pay-for-performance programs.
    Sinsky CA; Foreman-Hoffman V; Cram P
    J Gen Intern Med; 2008 Feb; 23(2):164-8. PubMed ID: 18163191
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada.
    Burden AM; Paterson JM; Solomon DH; Mamdani M; Juurlink DN; Cadarette SM
    Osteoporos Int; 2012 Mar; 23(3):1075-82. PubMed ID: 21604008
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates.
    Foster SA; Foley KA; Meadows ES; Johnston JA; Wang S; Pohl GM; Long SR
    BMC Womens Health; 2008 Dec; 8():24. PubMed ID: 19105828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on the use of bisphosphonates in the management of postmenopausal osteoporosis by obstetricians-gynecologists.
    Sunyecz JA; Derman R
    Obstet Gynecol Surv; 2007 Jun; 62(6):407-16. PubMed ID: 17511895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A systematic review of persistence and compliance with bisphosphonates for osteoporosis.
    Cramer JA; Gold DT; Silverman SL; Lewiecki EM
    Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to oral bisphosphonates: 30 more minutes in dosing instructions matter.
    Vytrisalova M; Touskova T; Ladova K; Fuksa L; Palicka V; Matoulkova P; Horak P; Stepan J
    Climacteric; 2015; 18(4):608-16. PubMed ID: 25495333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Considerations regarding adherence of anti-osteoporosis therapy.
    Lagari VS; McAninch E; Baim S
    Postgrad Med; 2015 Jan; 127(1):92-8. PubMed ID: 25526234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Side Effects, Physician Involvement, and Patient Perception in Non-Adherence with Oral Bisphosphonates.
    Goldshtein I; Rouach V; Shamir-Stein N; Yu J; Chodick G
    Adv Ther; 2016 Aug; 33(8):1374-84. PubMed ID: 27329383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
    Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
    Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost and consequences of noncompliance to oral bisphosphonate treatment.
    Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
    J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Osteoporosis management and the utilization of FRAX®: a survey amongst health care professionals of the Asia-Pacific.
    Korthoewer D; Chandran M;
    Arch Osteoporos; 2012; 7():193-200. PubMed ID: 23225297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compliance with treatment in osteoporosis patients--an ongoing problem.
    Sambrook P
    Aust Fam Physician; 2006 Mar; 35(3):135-7. PubMed ID: 16525527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis.
    Curtis JR; Xi J; Westfall AO; Cheng H; Lyles K; Saag KG; Delzell E
    Med Care; 2009 Mar; 47(3):334-41. PubMed ID: 19194337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
    Rietbrock S; Olson M; van Staa TP
    QJM; 2009 Jan; 102(1):35-42. PubMed ID: 18842684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term use of bisphosphonates in osteoporosis.
    Watts NB; Diab DL
    J Clin Endocrinol Metab; 2010 Apr; 95(4):1555-65. PubMed ID: 20173017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A retrospective database study of oral corticosteroid and bisphosphonate prescribing patterns in England.
    Chalitsios CV; Shaw DE; McKeever TM
    NPJ Prim Care Respir Med; 2020 Feb; 30(1):5. PubMed ID: 32054843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.